British pharmaceutical company AstraZeneca's hopes of developing a new prostate cancer pill were dashed after the company admitted that the drug failed to achieve the required results in the late clinical stage.
AstraZeneca had high hopes of their latest cancer pill, zibotentan, after two previous attempts had ended in failures.
However zibotentan failed to improve the overall survival chances in the Phase III study and the company confirmed that there will not be any regulatory submissions made for the approval of the drug.
More than 3,000 men took part in the study with the pill aimed among those patients who were not able to respond to other available treatments.
However the company added that two more studies looking at the effectiveness of the drug in different settings will continue to take place until the end of the study period.